Benefaction of probiotics for human health: A review

Journal of Food and Drug Analysis

Volumn 26, Issue 3, 2018, Pages 927-939

  George Kerry, Rout ^a   Patra, Jayanta Kumar ^b   Gouda, Sushanto ^c   Park, Yooheon ^b   Shin, Han Seung ^b   Das, Gitishree ^b  

^a Academy of Management and Information Technology   (India)

^b Dongguk University   (South Korea)

^c Amity Institutes of Wildlife Sciences (AIWS)   (India)

Author keywords

Human gut; Microbiota; Pathogenic; Probiotics; Symbiotic relationship

Indexed keywords

ARABINOXYLAN; ARABINOXYLAN OLIGOSACCHARIDE; BACTERIOCIN; BUTYRIC ACID; EXOPOLYSACCHARIDE; FRUCTOSE OLIGOSACCHARIDE; GALACTOSE OLIGOSACCHARIDE; INULIN; ISOMALTOOLIGOSACCHARIDE; LACTOSUCROSE; LACTULOSE; MICROBIAL PRODUCTS NOT CLASSIFIED ELSEWHERE; OLIGOSACCHARIDE; POLYPHOSPHATE; POSTBIOTIC AGENT; PREBIOTIC AGENT; PROBIOTIC AGENT; SACCHAROMYCES BOULARDII CONCENTRATE; SHORT CHAIN FATTY ACID; SUCRALOSE; SYNBIOTIC AGENT; UNCLASSIFIED DRUG; XYLOOLIGOSACCHARIDE;

AKKERMANSIA; ANGIOGENESIS; ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; BACILLUS; BACTEROIDES; BIFIDOBACTERIUM; BRAIN; CENTRAL NERVOUS SYSTEM; CROHN DISEASE; DIET SUPPLEMENTATION; ENTEROCOCCUS; HEALTH CARE; HUMAN; LACTOBACILLUS; LACTOCOCCUS; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRITIONAL HEALTH; OBESITY; PEDIOCOCCUS; PEPTOSTREPTOCOCCUS; PROPIONIBACTERIUM; REVIEW; SACCHAROMYCES; STREPTOCOCCUS; ULCERATIVE COLITIS; VERRUCOMICROBIA; ANIMAL; DIABETES MELLITUS; HEALTH; INTESTINE FLORA; NEOPLASM;

ANIMALS; DIABETES MELLITUS; GASTROINTESTINAL MICROBIOME; HEALTH; HUMANS; NEOPLASMS; OBESITY; PROBIOTICS;

EID: 85044654878     PISSN: 10219498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jfda.2018.01.002     Document Type: Review

References (120)

1. Bagchi, T., Traditional food & modern lifestyle: impact of probiotics. Indian J Med Res 140:3 (2014), 333–335.
2. Metchnikoff, E., Mitchell, P.C., (eds.) Essais optimistes, 1907, Heinemann, London.
3. Tissier, H., Tritement des infections intestinales par la methode de translormation de la flore bacterienne de lintestin. C R Soc Biol 60 (1906), 359–361 [in French].
4. Havenaar, R., Huis in't Veld, J.H.J., Probiotics: a general view. Wood, B.J.B., (eds.) The lactic acid bacteria in health and disease, 1992, Elsevier Applied Science, London, 151–170.
5. Aziz, Q., Dore, J., Emmanuel, A., Guarners, F., Quigley, E.M.M., Gut microbiota and gastrointestinal health: current concepts and future directions. Neuro Gastroenterol Motil 25 (2013), 4–15.
6. Slavin, J., Fiber and prebiotics: mechanisms and health benefits. Nutrients 5 (2013), 1417–1435.
7. Lloyd-Price, J., Abu-Ali, G., Huttenhower, C., The healthy human microbiome. Genome Med 8 (2016), 1–11.
8. Lewis, B.B., Buffie, C.G., Carter, R., Leiner, I., Toussaint, N.C., Miller, L., et al. Loss of microbiota-mediated colonization resistance to clostridium difficile infection is greater following oral vancomycin as compared with metronidazole. J Infect Dis 212 (2015), 1656–1665.
9. Perez-Cobas, A.E., Moya, A., Gosalbes, M.J., Latorre, A., Colonization resistance of the gut microbiota against clostridium difficile. Antibiotics 4 (2015), 337–357.
10. Scott, K.P., Antoine, J.-M., Midtvedt, T., van Hemert, S., Manipulating the gut microbiota to maintain health and treat disease. Microb Ecol Health Dis, 26, 2015 10.3402/mehd.v26.25877.
11. Pamer, E.G., Resurrecting the intestinal microbiota to combat antibiotic-resistant pathogens. Science 352 (2016), 535–538.
12. Qadir, M.I., Phage therapy: a modern tool to control bacterial infections. Pak J Pharm Sci 28 (2015), 265–270.
13. Rao, S.C., Athalye-Jape, G.K., Deshpande, G.C., Simmer, K.N., Patole, S.K., Probiotic supplementation and late-onset sepsis in preterm infants: a meta-analysis. Pediatrics 137 (2016), 1–16.
14. Kristensen, N.B., Bryrup, T., Allin, K.H., Nielsen, T., Hansen, T.H., Pedersen, O., Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: a systematic review of randomized controlled trials. Genome Med 8 (2016), 1–11.
15. Bakirtzi, K., Law, I.K.M., Xue, X., Iliopoulos, D., Shah, Y.M., Pothoulakis, C., Neurotensin promotes the development of colitis and intestinal angiogenesis via Hif-1α–miR-210 signaling. J Immunol 196 (2016), 4311–4321.
16. Chen, X., Yang, G., Song, J.-H., Xu, H., Li, D., Goldsmith, J., et al. Probiotic yeast inhibits VEGFR signaling and angiogenesis in intestinal inflammation. PLoS One 8 (2013), 1–7.
17. Kobyliak, N., Conte, C., Cammarota, G., Haley, A.P., Styriak, I., Gaspar, L., et al. Probiotics in prevention and treatment of obesity: a critical view. Nutr Metab 13 (2016), 1–13.
18. Gibson, G.R., Roberfroid, M.B., Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 125 (1995), 1401–1412.
19. Hamasalim, H.J., Synbiotic as feed additives relating to animal health and performance. Adv Microbiol 6 (2016), 288–302.
20. Bongaerts, G.P.A., Severijnen, R.S.V.M., A reassessment of the PROPATRIA study and its implications for probiotic therapy. Nature Biotechnol 34 (2016), 55–63.
21. Patel, R.M., Denning, P.W., Therapeutic use of prebiotics, probiotics, and postbiotics to prevent necrotizing enterocolitis: what is the current evidence?. Clin Perinatol 40 (2013), 11–25.
22. Islam, S.U., Clinical uses of probiotics. Medicine (Baltimore) 95 (2016), 1–5.
23. Ooi, M.F., Mazlan, N., Foo, H.L., Loh, T.C., Mohamad, R., Rahim, R.A., et al. Effects of carbon and nitrogen sources on bacteriocin-inhibitory activity of postbiotic metabolites produced by Lactobacillus plantarum I-UL4. Malays J Microbiol 11 (2015), 176–184.
24. Giorgetti, G.M., Brandimarte, G., Fabiocchi, F., Ricci, S., Flamini, P., Sandri, G., et al. Interactions between innate immunity, microbiota, and probiotics. J Immunol Res, 501361, 2015, 7.
25. Cicenia, A., Scirocco, A., Carabotti, M., Pallotta, L., Marignani, M., Severi, C., Postbiotic activities of lactobacilli-derived factors. J Clin Gastroenterol 48 (2014), S18–S22.
26. Rastall, R.A., Gibson, G.R., Recent developments in prebiotics to selectively impact beneficial microbes and promote intestinal health. Curr Opinion Biotechnol 32 (2015), 42–46.
27. Thomas, L.V., Probiotics-the journey continues. Int J Dairy Tech 69 (2016), 1–12.
28. Hutkins, R.W., Krumbeck, J.A., Bindels, L.B., Cani, P.D., Fahey, G., Goh, Y.J., et al. Prebiotics: why definitions matter. Curr Opin Biotechnol 37 (2016), 1–13.
29. Tanaka, R., Takayama, H., Morotomi, M., Kuroshima, T., Ueyama, S., Matsumoto, K., et al. Effects of administration of TOS and Bifidobacterium breve 4006 on the human fecal flora. Bifidobact Microflora 2 (1983), 17–24.
30. Pena, A.S., Intestinal flora, probiotics, prebiotics, synbiotics and novel foods. Rev Esp Enferm Dig 99 (2007), 653–658.
31. Pokusaeva, K., Fitzgerald, G.F., Sinderen, D., Carbohydrate metabolism in bifidobacteria. Genes Nutr 6 (2011), 285–306.
32. Tufarelli, V., Laudadio, V., An overview on the functional food concept: prospectives and applied researches in probiotics, prebiotics and synbiotics. J Exp Biol Agric Sci 4 (2016), 274–278.
33. Tejero-Sarinena, S., Barlow, J., Costabile, A., Gibson, G.R., Rowland, I., Antipathogenic activity of probiotics against Salmonella Typhimurium and Clostridium difficile in anaerobic batch culture systems: is it due to synergies in probiotic mixtures or the specificity of single strains?. Anaerobe 24 (2013), 60–65.
34. Kareem, K.Y., Ling, F.H., Chwen, L.T., Foong, O.M., Asmara, S.A., Inhibitory activity of postbiotic produced by strains of Lactobacillus plantarum using reconstituted media supplemented with inulin. Gut Pathog 6 (2014), 1–7.
35. Simova, E.D., Beshkova, D.B., Dimitrov, P., Characterization and antimicrobial spectrum of bacteriocins produced by lactic acid bacteria isolated from traditional Bulgarian dairy products. J Appl Microbiol 106 (2009), 692–701.
36. Ammor, S., Tauveron, G., Dufour, E., Chevallier, I., Antibacterial activity of lactic acid bacteria against spoilage and pathogenic bacteria isolated from the same meat small-scale facility. Screening and characterization of the antibacterial compounds. Food Control 17 (2006), 454–461.
37. Figueroa-Gonzalez, I., Cruz-Guerrero, A., Quijano, G., The benefits of probiotics on human health. J Microb Biochem Technol, S1, 2011, 003.
38. Waigankar, S.S., Patel, V., Role of probiotics in urogenital healthcare. J Midlife Health 2 (2011), 5–10.
39. Hanson, L., Vusse, L.V., Jerme, M., Abad, C.L., Safdar, N., Probiotics for treatment and prevention of urogenital infections in women: a systematic review. J Midwifery Womens Health 61 (2016), 339–355.
40. Chan, P.A., Robinette, A., Montgomery, M., Almonte, A., Cu-Uvin, S., Lonks, J.R., et al. Extra genital infections caused by Chlamydia trachomatis and Neisseria gonorrhoeae: a review of the literature. Infect Dis Obstet Gynecol, 5758387, 2016, 17.
41. International Diabetes Federation, Diabetes atlas. 2017, IDF Diabetes Atlas, Chausséede la Hulpe 166, 1170 Watermael-Boitsfort, Belgium http://www.diabetesatlas.org/resources/2017-atlas.html [Accessed 15 November 2017].
42. Iqbal, M.Z., Qadir, M.I., Hussain, T., Janbaz, K.H., Khan, Y.H., Ahmad, B., Probiotics and their beneficial effects against various diseases. Pak J Pharm Sci 27 (2014), 405–415.
43. Larsen, N., Vogensen, F.K., van-den-Berg, F.W., Nielsen, D.S., Andreasen, A.S., Pedersen, B.K., et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One 5 (2010), 1–10.
44. Barz, M.L., Anhe, F.F., Varin, T.V., Desjardins, Y., Levy, E., Roy, D., et al. Probiotics as complementary treatment for metabolic disorders. Diabetes Metab J 39 (2015), 291–303.
45. Barrett, H.L., Callaway, L.K., Nitert, M.D., Probiotics: a potential role in the prevention of gestational diabetes?. Acta Diabetol 49 (2012), 1–13.
46. Barrett, E., Ross, R.P., O'Toole, P.W., Fitzgerald, G.F., Stanton, C., γ-Aminobutyric acid production by culturable bacteria from the human intestine. J Appl Microbiol 113 (2012), 411–417.
47. Hu, C., Wong, F.S., Wen, L., Type 1 diabetes and gut microbiota: friend or foe?. Pharmacol Res 98 (2015), 9–15.
48. Ljungberg, M., Korpela, R., Ilonen, J., Ludvigsson, J., Vaarala, O., Probiotics for the prevention of beta cell autoimmunity in children at genetic risk of type-1 diabetes-the PRODIA study. Ann N Y Acad Sci 1079 (2006), 360–364.
49. Hartstra, A.V., Bouter, K.E.C., Backhed, F., Nieuwdorp, M., Insights into the role of the microbiome in obesity and type 2 diabetes. Diabetes Care 38 (2015), 159–165.
50. Grover, S., Rashmi, H.M., Srivastava, A.K., Batish, V.K., Probiotics for human health-new innovations and emerging trends. Gut Pathog 4 (2012), 1–14.
51. Karimi, G., Sabran, M.R., Jamaluddin, R., Parvaneh, K., Mohtarrudin, N., Ahmad, Z., et al. The anti-obesity effects of Lactobacillus casei strain Shirota versus Orlistat on high fat diet-induced obese rats. Food Nutr Res 59 (2015), 1–8.
52. Kang, J.-H., Yun, S.-I., Park, M.-H., Park, J.-H., Jeong, S.-Y., Park, H.-O., Anti-obesity effect of Lactobacillus gasseri BNR17 in high-sucrose diet-induced obese mice. PLoS One 8 (2013), 1–8.
53. Palumbo, V.D., Marcello, R., Gammazza, A.M., Carini, F., Damiani, P., Damiano, G., et al. The long-term effects of probiotics in the therapy of ulcerative colitis: a clinical study. Biomed Pap 160 (2016), 372–377.
54. Cammarota, G., Ianiro, G., Cianci, R., Bibbo, S., Gasbarrini, A., Curro, D., The involvement of gut microbiota in inflammatory bowel disease pathogenesis: potential for therapy. Pharmacol Ther 149 (2015), 191–212.
55. Cammarota, G., Pecere, S., Ianiro, G., Masucci, L., Curro, D., Principles of DNA-based gut microbiota assessment and therapeutic efficacy of fecal microbiota transplantation in gastrointestinal diseases. Dig Dis 34 (2016), 279–285.
56. Spiller, R., Irritable bowel syndrome: new insights into symptom mechanisms and advances in treatment. F1000Research 5 (2016), 1–11.
57. Curro, D., Ianiro, G., Pecere, S., Bibbo, S., Cammarota, G., Probiotics, fiber and herbal medicinal products for functional and inflammatory bowel disorders. Br J Pharmacol 173 (2016), 61–68.
58. Shahverdi, E., Probiotics and gastrointestinal diseases. Int J Dig Dis 2 (2016), 1–2.
59. Gowri, R.S., Meenambigai, P., Prabhavathi, P., Rajeswari, P.R., Yesudoss, L.A., Probiotics and its effects on human health-a review. Int J Curr Microbiol Appl Sci 5 (2016), 384–392.
60. World Health Organization, Cancer fact sheet 2017. 2017, World Health Organization, Switzerland.
61. Vidya, S., Thiruneelakandan, G., Probiotic potentials of lactobacillus and its anti-cancer activity. Int J Curr Res 7 (2015), 20680–20684.
62. Gayathri, D., Rashmi, B.S., Anti-cancer properties of probiotics: a natural strategy for cancer prevention. EC Nutrition 5 (2016), 1191–1202.
63. Vafaeie, F., Critical review on probiotics and its effect on cancer, vol. 2, 2016, Cancer Press, 30–34.
64. So, S.S., Wan, M.L., El-Nezami, H., Probiotics-mediated suppression of cancer. Curr Opinion Oncol 29 (2017), 62–72.
65. Kahouli, I., Malhotra, M., Alaoui-Jamali, M.A., Prakash, S., In-vitro characterization of the anti-cancer activity of the probiotic bacterium Lactobacillus fermentum NCIMB 5221 and potential against colorectal cancer cells. J Cancer Sci Ther 7 (2015), 224–235.
66. Awaisheh, S.S., Obeidat, M.M., Al-Tamimi, H.J., Assaf, A.M., EL-Qudah, J.M., Al-khazaleh, J.M., et al. In vitro cytotoxic activity of probiotic bacterial cell extracts against Caco-2 and HRT-18 colorectal cancer cells. Milk Sci Int 69 (2016), 27–31.
67. Akelma, A.Z., Topcu, Z.I.K., Probiotics and allergic disease. World J Immunol 6I (2016), 75–82.
68. Song, S., Lee, S.J., Park, D.-J., Oh, S., Lim, K.-T., The anti-allergic activity of Lactobacillus plantarum L67 and its application to yogurt. J Dairy Res 99 (2016), 9372–9382.
69. Takeda, S., Hidaka, M., Yoshida, H., Takeshita, M., Kikuchi, Y., Tsend-Ayush, C., et al. Antiallergic activity of probiotics from Mongolian dairy products on type I allergy in mice and mode of antiallergic action. J Funct Foods 9 (2014), 60–69.
70. Flkman, J., Angiogenesis. Annu Rev Med 57 (2006), 1–18.
71. Folkman, J., Angiogenesis: an organizing principle for drug discovery?. Nat Rev Drug Discov 6 (2007), 273–286.
72. Mayer, E.A., Tillisch, K., Gupta, A., Gut/brain axis and the microbiota. J Clin Invest 125 (2015), 926–938.
73. Tillisch, K., The effects of gut microbiota on CNS function in humans. Gut Microbes 5 (2014), 404–410.
74. Umbrello, G., Esposito, S., Microbiota and neurologic diseases: potential effects of probiotics. J Transl Med 14 (2016), 1–11.
75. Messaoudi, M., Lalonde, R., Violle, N., Javelot, H., Desor, D., Nejdi, A., et al. Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. Br J Nutr 105 (2011), 755–764.
76. Rao, A.V., Bested, A.C., Beaulne, T.M., Katzman, M.A., Iorio, C., Berardi, J.M., et al. A randomized, double-blind, placebo-controlled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome. Gut Pathog 1 (2009), 1–6.
77. Szajewska, H., What are the indications for using probiotics in children?. Arch Dis Child 101 (2016), 398–403.
78. Daliri, E.B.M., Oh, D.H., Lee, B.H., Psychobiotics; a promise for neurodevelopmental therapy. J Probiotics Health 4 (2016), 1–4.
79. Nogueiras, R., Romero-Pico, A., Vazquez, M.J., Novelle, M.G., Lopez, M., The opioid system and food intake: homeostatic and hedonic mechanisms. Obes Facts 5 (2012), 196–207.
80. Kelly, G., Inulin-type prebiotics – a review: Part 1. Altern Med Rev 13:4 (2008), 315–329.
81. Moreno, F.J., Corzo, N., Montilla, A., Villamiel, M., Olano, A., Current state and latest advances in the concept, production and functionality of prebiotic oligosaccharides. Curr Opin Food Sci 13 (2017), 50–55.
82. Villamiel, M., Montilla, A., Olano, A., Corzo, N., Production and bioactivity of oligosaccharides derived from lactose. Moreno, F.J., Sanz, M.L., (eds.) Food oligosaccharides: production, analysis and bioactivity, 2014, Wiley Blackwell, 137–167.
83. Trollope, K.M., van Wyk, N., Kotjomela, M.A., Volschenk, H., Sequence and structure-based prediction of fructosyltransferase activity for functional sub classification of fungal GH32 enzymes. FEBS J 282 (2015), 4782–4796.
84. Devlamynck, T., Te Poele, E.M., Meng, X., van Leeuwen, S.S., Dijkhuizen, L., Glucansucrase Gtf180-DN of Lactobacillus reuteri 180: enzyme and reaction engineering for improved glycosylation of non-carbohydrate molecules. Appl Microbiol Biotechnol 100 (2016), 7529–7539.
85. Schmid, J., Heider, D., Wendel, N.J., Sperl, N., Sieber, V., Bacterial glycosyltransferases: challenges and opportunities of a highly diverse enzyme class toward tailoring natural products. Front Microbiol, 7, 2016, 182.
86. FDA, GRAS notice (GRN) No. 571. 20–Fucosyllactose. 2015 http://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/NoticeInventory/default.htm.
87. Collins, S., Reid, G., Distant site effects of ingested prebiotics. Nutrients, 8, 2016, 523.
88. Zhou, Y., Kruger, C., Ravi, G.S., Kumar, D.P.S., Vijayasarathi, S.K., Lavingia, M., et al. Safety evaluation of galactooligosaccharides: sub chronic oral toxicity study in Sprague-Dawley rats. Toxicol Res Appl 1 (2017), 1–12.
89. Savignac, H.M., Corona, G., Mills, H., Chen, L., Spencer, J.P., Tzortzis, G., et al. Prebiotic feeding elevates central brain derived neurotrophic factor, N-methyl-d-aspartate receptor subunits and d-serine. Neurochem Int 63 (2013), 756–764.
90. Williams, S., Chen, L., Savignac, H.M., Tzortzis, G., Anthony, D.C., Burnet, P.W., Neonatal prebiotic (BGOS) supplementation increases the levels of synaptophysin, GluN2A-subunits and BDNF proteins in the adult rat hippocampus. Synapse 70 (2016), 121–124.
91. Pretorius, R., Prescott, S.L., Palmer, D.J., Taking a prebiotic approach to early immunomodulation for allergy prevention. Expert Rev Clin Immunol 14:1 (2018), 43–51.
92. Hong, K.B., Jeong, M., Han, K.S., Kim, J.H., Park, Y., Suh, H.J., Photoprotective effects of galacto-oligosaccharide and/or Bifidobacterium longum supplementation against skin damage induced by ultraviolet irradiation in hairless mice. Int J Food Sci Nutr 66 (2015), 923–930.
93. Gibson, G.R., Hutkins, R., Sanders, M.L., Prescott, S.L., Reimer, R.A., Salminen, S.J., et al. The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol 14 (2017), 491–502.
94. Kano, M., Masuoka, N., Kaga, C., Sugimoto, S., Iizuka, R., Manabe, K., et al. Consecutive intake of fermented milk containing Bifidobacterium breve strain Yakult and galacto-oligosaccharides benefits skin condition in healthy adult women. Biosci Microbiota Food Health 32 (2013), 33–39.
95. Roberfroid, M., Gibson, G.R., Hoyles, L., McCartney, A.L., Rastall, R., Rowland, I., et al. Prebiotic effects: metabolic and health benefits. Br J Nutr 104:2 (2010), S1–S63.
96. Yoo, J.Y., Kim, S.S., Probiotics and prebiotics: present status and future perspectives on metabolic disorders. Nutrients, 8(3), 2016, 173.
97. Dixit, Y., Wagle, A., Vakil, B., Patents in the field of probiotics, prebiotics, synbiotics: a review. J Food Microbiol Saf Hygiene 1 (2016), 1–13.
98. Nguyen, H.-T., Truong, D.-H., Kouhounde, S., Ly, S., Razafindralambo, H., Delvigne, F., Biochemical engineering approaches for increasing viability and functionality of probiotic bacteria. Int J Mol Sci 17 (2016), 1–18.
99. Eid, R., Jakee, J.E., Rashidy, A., Asfour, H., Omara, S., Kandil, M.M., et al. Potential antimicrobial activities of probiotic Lactobacillus strains isolated from raw milk. J Probiotics Health 4 (2016), 1–8.
100. Onyenweaku, F., Obeagu, E.I., Ifediora, A.C., Nwandikor, U.U., Health benefits of probiotics. Int J Innov Appl Res 4 (2016), 21–30.
101. Sornplang, P., Piyadeatsoontorn, S., Probiotic isolates from unconventional sources: a review. J Anim Sci Tech 58 (2016), 1–11.
102. Arora, T., Singh, S., Sharma, R.K., Probiotics: interaction with gut microbiome and antiobesity potential. Nutrition 29 (2013), 591–596.
103. Westermann, C., Gleinser, M., Corr, S.C., Riedel, C.U., A critical evaluation of Bifidobacterial adhesion to the host tissue. Front Microbiol 7 (2016), 1–8.
104. Tsilingiri, K., Rescigno, M., Postbiotics: what else?. Benef Microbes 4 (2012), 101–107.
105. Zagato, E., Mileti, E., Massimiliano, L., Fasano, F., Budelli, A., Penna, G., et al. Lactobacillus paracasei CBA L74 metabolic products and fermented milk for infant formula have anti- inflammatory activity on dendritic cells in vitro and protective effects against colitis and an enteric pathogen in vivo. PLoS One 9 (2014), 1–14.
106. Tiptiri-Kourpeti, A., Spyridopoulou, K., Santarmaki, V., Aindelis, G., Tompoulidou, E., Lamprianidou, E.E., et al. Lactobacillus casei exerts anti-proliferative effects accompanied by apoptotic cell death and up-regulation of TRAIL in colon carcinoma cells. PLoS One 11 (2016), 1–20.
107. Sabater-Molina, M., Larque, E., Torrella, F., Zamora, S., Dietary fructo-oligosaccharides and potential benefits on health. J Physiol Biochem 65 (2009), 315–328.
108. Patel, S., Goyal, A., The current trends and future perspectives of prebiotics research: a review. 3 Biotech 2 (2012), 115–125.
109. Oliveira, R.P.D.S., Florence, A.C.R., Perego, P., De Oliveira, M.N., Converti, A., Use of lactulose as prebiotic and its influence on the growth, acidification profile and viable counts of different probiotics in fermented skim milk. Int J Food Microbiol 145 (2011), 22–27.
110. Zhou, X., Ruan, Z., Huang, X., Zhou, Y., Liu, S., Yin, Y., The prebiotic lactosucrose modulates gut metabolites and microbiota in intestinal inflammatory rats. Food Sci Biotechnol 23 (2014), 157–163.
111. Torres, D.P.M., Goncalves, M.P.F., Teixeira, J.A., Rodrigues, L.R., Galacto-oligosaccharides: production, properties, applications, and significance as prebiotics. Compr Rev Food Sci Food Saf 9 (2010), 438–454.
112. Rycroft, C.E., Jones, M.R., Gibson, G.R., Rastall, R.A., A comparative in vitro evaluation of the fermentation properties of prebiotic oligosaccharides. J Appl Microbiol 91 (2001), 878–887.
113. Aachary, A.A., Prapulla, S.G., Xylooligosaccharides (XOS) as an emerging prebiotic: microbial synthesis, utilization, structural characterization, bioactive properties, and applications. Compr Rev Food Sci Food Saf 10 (2011), 1–16.
114. Moro, G., Arslanoglu, S., Stahl, B., Jelinek, J., Wahn, U., Boehm, G., A mixture of prebiotic oligosaccharides reduces the incidence of atopic dermatitis during the first six months of age. Arch Dis Child 91 (2006), 814–819.
115. Fuentes-Zaragoza, E., Sanchez-Zapata, E., Sendra, E., Sayas, E., Navarro, C., Fernandez-Lopez, J., et al. Resistant starch as prebiotic: a review. Starch Starke 63 (2011), 406–415.
116. Hoseinifar, S.H., Ahmadi, A., Raeisi, M., Hoseini, S.H., Khalili, M., Behnampour, N., Comparative study on immunomodulatory and growth enhancing effects of three prebiotics (galactooligosaccharide, fructooligosaccharide and inulin) in common carp (Cyprinus carpio). Fish Shellfish Immunol 58 (2016), 1–10.
117. Han, W.-C., Byun, S.-H., Kim, M.-H., Sohn, E.H., Lim, J.D., Um, B.H., et al. Production of lactosucrose from sucrose and lactose by a levansucrase from Zymomonas mobilis. J Microbiol Biotechnol 19 (2009), 1153–1160.
118. Macfarlane, G.T., Steed, H., Macfarlane, S., Bacterial metabolism and health-related effects of galacto-oligosaccharides and other prebiotics. J Appl Microbiol 104 (2008), 305–344.
119. Bartosch, S., Woodmansey, E.J., Paterson, J.C., McMurdo, M.E., Macfarlane, G.T., Microbiological effects of consuming a synbiotic containing Bifidobacterium bifidum, Bifidobacterium lactis, and oligofructose in elderly persons, determined by real-time polymerase chain reaction and counting of viable bacteria. Clin Infect Dis 40 (2005), 28–37.
120. Bird, A.R., Brown, I.L., Topping, D.L., Starches, resistant starches, the gut microflora and human health. Curr Issues Intest Microbiol 1 (2000), 25–37.